SYDNEY, Feb 17, 2026, 17:27 AEDT — The market has closed.
Pro Medicus Ltd closed up 7.7% at A$125.96 on Tuesday, topping Australia’s S&P/ASX 200, which notched a 0.24% gain. (Investing.com)
The rebound stands out as traders keep wrestling with how to price “growth” when expensive software stocks keep taking a hit. With Lunar New Year thinning out activity across Asia and Wall Street dark for Presidents’ Day, local momentum and earnings are doing most of the work setting direction. (Reuters)
For Pro Medicus, it’s all about execution now—turning those big hospital deals from signatures into working, billable systems, and doing it fast.
Pro Medicus reported a 28.4% jump in revenue to A$124.8 million for the half-year ended Dec. 31, according to its Feb. 12 ASX filing. Underlying profit before tax climbed 29.7% to A$90.7 million. Net profit after tax surged to A$171.2 million, driven by A$149.1 million in unrealised gains from its 4D Medical stake—those gains haven’t been realised as cash. The company announced a fully franked interim dividend of 32 cents a share and said it continues to carry no debt. (Company Announcements)
Chief executive Sam Hupert noted the company’s biggest “go-live” happened late in the half, which meant “it had limited financial impact in the half but will have in the second half.” Hupert called Pro Medicus “a capital-light, software-only model,” pointing this out while AI-driven headlines sent software valuations swinging. (Company Announcements)
Pro Medicus develops imaging software for radiologists and clinicians—think storage, processing, and reading of medical scans. The RIS manages workflow, while the PACS acts as both library and viewer for images.
Revenue at the company tends to swing, since large deployments rarely land on schedule. If a rollout slips, usage fees and support sales get deferred to another quarter—contract or no contract.
Still, risks remain. A stumble in execution, and suddenly doubts about growth resurface. Investors, for their part, are quick to discount any one-off gains when sizing up real earnings strength.
Shares of Pro Medicus finished the session at A$125.96, bouncing around from A$116.98 up to A$127.55, per Intelligent Investor. Investors have their eyes on Feb. 26—the ex-dividend date for the interim 32-cent payout. That dividend lands on March 20. (intelligentinvestor.com.au)
